Journal article
A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
Abstract
PURPOSE: The optimal frequency for cardiac monitoring of left ventricular ejection fraction (LVEF) in patients receiving trastuzumab-based therapy for early breast cancer (EBC) is unknown. We conducted a randomized controlled trial comparing 3- versus 4-monthly cardiac monitoring.
PATIENTS AND METHOD: Patients scheduled to receive trastuzumab-containing cancer therapy for EBC with normal (>53%) baseline LVEF were randomized to undergo LVEF …
Authors
Dent S; Fergusson D; Aseyev O; Stober C; Pond G; Awan AA; McGee SF; Ng TL; Simos D; Vandermeer L
Journal
Current Oncology, Vol. 28, No. 6, pp. 5073–5083
Publisher
MDPI
DOI
10.3390/curroncol28060427
ISSN
1198-0052